Close Menu

NEW YORK (360Dx) — Vermillion said on Thursday that its OVA1 ovarian cancer test will now receive preferred coverage from Blue Cross Blue Shield of Texas and Blue Cross Blue Shield of Arizona as an in-network covered test.

OVA1 is a proteomic test that is meant to help doctors evaluate whether a patient with a pelvic mass is at high risk of having ovarian cancer and should be referred to a gynecologic oncologist for surgery.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Jul
30
Sponsored by
Mission Bio

This webinar will outline a project that performs large-scale and integrative single-cell genome and transcriptome profiling of pediatric acute lymphoblastic leukemia (ALL) cases at diagnosis, during drug treatment, and in case of relapse.

Jul
31
Sponsored by
Thermo Fisher Scientific

This webinar will provide a first-hand look at how a molecular laboratory validated and implemented a targeted next-generation sequencing-based myeloid assay to expedite the assessment of myeloid malignancies and assist in the understanding of myeloid cancers.